✦ LIBER ✦

On the mechanism of action of vitamin E for nonalcoholic steatohepatitis

✍ Scribed by Hong-Fang Ji; Liang Shen

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 632 KB
Volume: 53
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.23950

No coin nor oath required. For personal study only.

✦ Synopsis

Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 lg: NEPTUNE study.

📜 SIMILAR VOLUMES

A pilot study of pioglitazone treatment

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

✍ Kittichai Promrat; Glen Lutchman; Gabriel I. Uwaifo; Renee J. Freedman; Alejandr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibrosis and cirrhosis. NASH is considered one of the clinical features of the metabolic syndrome in which insulin resistance p

Randomized controlled trial testing the

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

✍ Kittichai Promrat; David E. Kleiner; Heather M. Niemeier; Elizabeth Jackvony; Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB 👁 1 views

Nonalcoholic steatohepatitis (NASH) is a chronic progressive liver disease that is strongly associated with obesity. Currently, there is no approved therapy for NASH. Weight reduction is typically recommended, but efficacy data are lacking. We performed a randomized controlled trial to examine the e

One step at a time: Identification and v

One step at a time: Identification and validation of biomarkers for nonalcoholic steatohepatitis

✍ Jayant A. Talwalkar 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 1 views

The effects of discontinuing pioglitazon

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

✍ Glen Lutchman; Apurva Modi; David E. Kleiner; Kittichai Promrat; Theo Heller; Ma 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

Ursodeoxycholic acid for treatment of no

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

✍ Keith D. Lindor; Kris V. Kowdley; E. Jenny Heathcote; M. Edwyn Harrison; Roberta 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of

The effects of 48 weeks of rosiglitazone

The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis

✍ Stephen H. Caldwell; James T. Patrie; Elizabeth M. Brunt; Jan A. Redick; Christi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

Rosiglitazone, a thiazolidinedione peroxisome proliferator-activated receptor gamma ligand, reduces disease activity in nonalcoholic steatohepatitis (NASH), a disease associated with hepatocyte mitochondrial crystalline inclusions that are not seen in animal models of NASH. In human and animal studi